Literature DB >> 6383029

Effect of danazol on solubilization of immune deposits in patients with IgA nephropathy.

Y Tomino, H Sakai, M Miura, T Suga, M Endoh, Y Nomoto.   

Abstract

A study on the solubilization of glomerular immune deposits by administration of danazol in patients with IgA nephropathy is described. A clinical trial on danazol was performed in seven patient with IgA nephropathy. Administration of danazol was effective in improving proteinuria in patients with IgA nephropathy. In vitro effects of patients' sera on solubilization of glomerular immune deposits were examined in parallel studies. Renal biopsy specimens obtained from IgA nephropathy were incubated with fresh patients' sera before and after administration of danazol at 37 degrees C for one hour in plastic test tubes. The sections were stained with FITC-labeled heavy chain-specific anti-human IgA antiserum and then examined with a fluorescent microscope. It was shown that the solubilization of glomerular immune deposits by sera after administration of danazol from patients with IgA nephropathy was significantly higher than that by sera before such treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6383029     DOI: 10.1016/s0272-6386(84)80061-x

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  4 in total

Review 1.  Experimental IgA nephropathy: factors influencing IgA-immune complex deposition in the glomerulus.

Authors:  A Chen; C H Wei; W H Lee; C Y Lin
Journal:  Springer Semin Immunopathol       Date:  1994

Review 2.  IgA nephropathy in children and adults.

Authors:  N Yoshikawa; H Nakamura; H Ito
Journal:  Springer Semin Immunopathol       Date:  1994

3.  Treatment of severe IgA nephropathy in children.

Authors:  S P Andreoli; J M Bergstein
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

4.  IgA nephropathy in hereditary angioedema.

Authors:  J Srinivasan; P Beck
Journal:  Postgrad Med J       Date:  1993-02       Impact factor: 2.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.